NAGE Niagen Bioscience Inc
$2.98
$0.07
(2.29%)
Closed $2.98
$0.00
(0.00%)
After Hours
51
Neutral Sentiment
How do you feel about NAGE?
Ad free · Full sentiment data · Expanded watchers · Advanced search · No credit card required.
Advertisement|
Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the publication of independent preclinical research in Nature Communications led by a team at Sichuan Agricultural University...
Business Wire
Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces today that its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged Red Sky Partners, a life sciences strategic advisory firm...
Business Wire
Niagen Bioscience to Present at Canaccord Genuitys Well Summit
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuitys Well...
Business Wire
Niagen Bioscience to Present at Longevity Investors Conference
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the Longevity Investors Conference, taking place from September 14 to 17, 2026, in...
Business Wire
Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate in the Nasdaq X LD Micro Inaugural SF Summit on Wednesday, September 9, 2026, in San...
Business Wire
Niagen Bioscience Expands Tru Niagen Retail Footprint with GNC and Sams Club
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that Tru Niagen, the number one healthy-aging NAD-boosting supplement in the United States, is now available at GNC and Sams Club...
Business Wire
Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will present at the Midwest IDEAS Investor Conference on Thursday, August 27, 2026, at The InterContinental...
Business Wire
Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that Tru Niagen, the number one healthy-aging NAD+ supplement in the United States, is now available at Walmart.com. The launch...
Business Wire
Niagen Bioscience (NAGE) Meets Q2 Earnings Estimates
Niagen Bioscience (NAGE) delivered earnings and revenue surprises of 0.00% and -0.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks